§Patients are eligible for assessment of transfusion independence if they have completed the parent study or achieved transfusion independence or will not achieve transfusion independence in the parent study.1
ZYNTEGLO is indicated for the treatment of patients 12 years and older with transfusion‑dependent β‑thalassaemia (TDT) who do not have a β0/β0 genotype, for whom haematopoietic stem cell (HSC) transplantation is appropriate but an HLA-matched related HSC donor is not available.
ZYNTEGLO has been granted conditional authorisation. This means that there is more evidence to come about the medicine, which bluebird bio will provide. Every year, the European Medicines Agency will review any new information that becomes available.2